Advances in the prevention of Alzheimer's disease and dementia

Journal of Internal Medicine

Volumn 275, Issue 3, 2014, Pages 229-250

  Solomon, A ^a,b   Mangialasche, F ^a   Richard, E ^c   Andrieu, S ^d   Bennett, D A ^e   Breteler, M ^f   Fratiglioni, L ^a   Hooshmand, B ^a   Khachaturian, A S ^g   Schneider, L S ^h   Skoog, I ⁱ   Kivipelto, M ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^g Campaign to Prevent Alzheimer's Disease by 2020 PAD2020   (United States)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Alzheimer's disease; Biomarkers; Clinical trials; Dementia; Prevention

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; BIOLOGICAL MARKER;

AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ALZHEIMER DISEASE; ARTICLE; BLOOD PRESSURE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COGNITIVE RESERVE; DEMENTIA; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; ENVIRONMENTAL FACTOR; FAMILY HISTORY; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; INTERVENTION STUDY; LIFESTYLE; MEMORY DISORDER; META ANALYSIS (TOPIC); NONHUMAN; OBSERVATIONAL STUDY; PHYSICAL ACTIVITY; PRIMARY PREVENTION; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REHABILITATION; RISK FACTOR; SECONDARY PREVENTION; UNDERWEIGHT;

ALZHEIMER'S DISEASE; BIOMARKERS; CLINICAL TRIALS; DEMENTIA; PREVENTION;

AGING; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COGNITION; DEMENTIA; EARLY DIAGNOSIS; HUMANS; LONGITUDINAL STUDIES; PREVENTIVE MEDICINE; PRODROMAL SYMPTOMS; RISK FACTORS;

EID: 84895734354     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12178     Document Type: Article

References (102)

1. Mangialasche F, Kivipelto M, Solomon A, Fratiglioni L. Dementia prevention: current epidemiological evidence and future perspective. Alzheimer's Res Ther 2012; 4: 6.
2. Dubois B, Feldman HH, Jacova C et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol 2010; 9: 1118-27.
3. Dubois B, Feldman HH, Jacova C et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6: 734-46.
4. McKhann GM, Knopman DS, Chertkow H et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263-9.
5. Albert MS, DeKosky ST, Dickson D et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 270-9.
6. Sperling RA, Aisen PS, Beckett LA et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 280-92.
7. Richard E, Schmand B, Eikelenboom P, Westendorp RG, Van Gool WA. The Alzheimer myth and biomarker research in dementia. J Alzheimers Dis 2012; 31(Suppl. 3): S203-9.
8. APA. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5). Arlington, VA: American Psychiatric Publishing, 2013.
9. Savva GM, Wharton SB, Ince PG, Forster G, Matthews FE, Brayne C. Age, neuropathology, and dementia. New Engl J Med 2009; 360: 2302-9.
10. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Annals of Neurol 2009; 66: 200-8.
11. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet 2012; 380: 1441-3.
12. Gorelick PB, Scuteri A, Black SE et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 2011; 42: 2672-713.
13. Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012; 8: 1-13.
14. Bateman RJ, Xiong C, Benzinger TL et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. New Engl J Med 2012; 367: 795-804.
15. Bennett DA, Wilson RS, Boyle PA, Buchman AS, Schneider JA. Relation of neuropathology to cognition in persons without cognitive impairment. Annals Neurol 2012; 72: 599-609.
16. Sojkova J, Zhou Y, An Y et al. Longitudinal patterns of beta-amyloid deposition in nondemented older adults. Arch Neurol 2011; 68: 644-9.
17. Esiri MM, Chance SA. Cognitive reserve, cortical plasticity and resistance to Alzheimer's disease. Alzheimer's Res Ther 2012; 4: 7.
18. Stern Y. Cognitive reserve in ageing and Alzheimer's disease. Lancet Neurol 2012; 11: 1006-12.
19. Katzman R, Terry R, DeTeresa R et al. Clinical, pathological, and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Annals Neurol 1988; 23: 138-44.
20. Honer WG, Barr AM, Sawada K et al. Cognitive reserve, presynaptic proteins and dementia in the elderly. Translat Psych 2012; 2: e114.
21. Iacono D, Markesbery WR, Gross M et al. The Nun study: clinically silent AD, neuronal hypertrophy, and linguistic skills in early life. Neurology 2009; 73: 665-73.
22. Iacono D, O'Brien R, Resnick SM et al. Neuronal hypertrophy in asymptomatic Alzheimer disease. J Neuropathol Exp Neurol 2008; 67: 578-89.
23. Wilson RS, Nag S, Boyle PA et al. Neural reserve, neuronal density in the locus coeruleous and cognitive decline. Neurology 2013; 80: 1202-8.
24. CFAS. NGotMRCCFaASM. Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001; 357: 169-75.
25. Sonnen JA, Larson EB, Crane PK et al. Pathological correlates of dementia in a longitudinal, population-based sample of aging. Annal Neurol 2007; 62: 406-13.
26. White L, Small BJ, Petrovitch H et al. Recent clinical-pathologic research on the causes of dementia in late life: update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol 2005; 18: 224-7.
27. Chui HC, Zheng L, Reed BR, Vinters HV, Mack WJ. Vascular risk factors and Alzheimer's disease: are these risk factors for plaques and tangles or for concomitant vascular pathology that increases the likelihood of dementia? An evidence-based review. Alzheimer's Res Ther 2012; 4: 1.
28. Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS. The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study. Lancet Neurol 2006; 5: 406-12.
29. Boyle PA, Buchman AS, Wilson RS, Yu L, Schneider JA, Bennett DA. Effect of purpose in life on the relation between Alzheimer disease pathologic changes on cognitive function in advanced age. Arch Gen Psychiatry 2012; 69: 499-505.
30. Brayne C, Ince PG, Keage HA et al. Education, the brain and dementia: neuroprotection or compensation? Brain 2010; 133: 2210-6.
31. Riley KP, Snowdon DA, Desrosiers MF, Markesbery WR. Early life linguistic ability, late life cognitive function, and neuropathology: findings from the Nun Study. Neurobiol Aging 2005; 26: 341-7.
32. Wilson RS, Krueger KR, Arnold SE et al. Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry 2007; 64: 234-40.
33. Wilson RS, Scherr PA, Schneider JA, Tang Y, Bennett DA. Relation of cognitive activity to risk of developing Alzheimer disease. Neurology 2007; 69: 1911-20.
34. Wilson RS, Schneider JA, Arnold SE, Bienias JL, Bennett DA. Conscientiousness and the incidence of Alzheimer disease and mild cognitive impairment. Arch Gen Psychiatry 2007; 64: 1204-12.
35. Hakansson K, Rovio S, Helkala EL et al. Association between mid-life marital status and cognitive function in later life: population based cohort study. BMJ (Clinical Research ed) 2009; 339: b2462.
36. Williams JW, Plassman BL, Burke J, Holsinger T, Benjamin S. Preventing Alzheimer's Disease and Cognitive Decline. Evidence Report/Technology Assessment No. 193. (Prepared by the Duke Evidence-Based Practice Center Under Contract No. HHSA 290-2007-10066-I.). Rockville, MD: Agency for Healthcare Research and Quality: AHRQ Publication No. 10-E005, 2010.
37. Hill AB. The environment and disease: association or causation? Proceed Royal Soc Med 1965; 58: 295-300.
38. Rothman KJ, Lash TL, Greenland S. Causation and Causal Inference Modern Epidemiology, 3rd edn. Philadelphia, PA, USA: Lippicott Williams & Wilkins, 2008; 5-31.
39. Lucas RM, McMichael AJ. Association or causation: evaluating links between "environment and disease". Bull World Health Organ 2005; 83: 792-5.
40. Fratiglioni L, Wang HX. Brain reserve hypothesis in dementia. J Alzheimers Dis 2007; 12: 11-22.
41. Fratiglioni L, Qiu C, Wang HX et al. Risk Factors for Dementia. The Swedish Council on Technology Assessment in Health Care (SBU). Report no. 172E, 2008; Volume 1, chapter 8, pp.317-494; http://sbu.se/en/ (last accessed 03.01.2014).
42. Vartiainen E, Laatikainen T, Peltonen M et al. Thirty-five-year trends in cardiovascular risk factors in Finland. Int J Epidemiol 2010; 39: 504-18.
43. Finucane MM, Stevens GA, Cowan MJ et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011; 377: 557-67.
44. Zhi X, Joas E, Waern M, Ostling S, Borjesson-Hanson A, Skoog I. Prevalence of cardiovascular disorders and risk factors in two 75-year-old birth cohorts examined in 1976-1977 and 2005-2006. Aging Clin Exp Res 2013; 25: 377-83.
45. Schrijvers EM, Verhaaren BF, Koudstaal PJ, Hofman A, Ikram MA, Breteler MM. Is dementia incidence declining?: Trends in dementia incidence since 1990 in the Rotterdam Study. Neurology 2012; 78: 1456-63.
46. Qiu C, von Strauss E, Bäckman L, Winblad B, Fratiglioni L. 20-year changes in dementia occurrence suggest decreasing incidence in central Stockholm, Sweden. Neurology 2013; 80: 1888-94.
47. Fratiglioni L, Qiu C. Prevention of cognitive decline in ageing: dementia as the target, delayed onset as the goal. Lancet Neurol 2011; 10: 778-9.
48. Tolppanen AM, Solomon A, Soininen H, Kivipelto M. Midlife vascular risk factors and Alzheimer's disease: evidence from epidemiological studies. J Alzheimers Dis 2013; 32: 531-40.
49. Qiu C, Kivipelto M, Fratiglioni L. Preventing Alzheimer disease and cognitive decline. Ann Intern Med 2011; 154: 211; author reply 2-3.
50. DZNE. German Center for Neurodegenerative Diseases within the Helmholtz Association. Epidemiologic research. 2013. http://www.dzne.de/en/research/research-areas/population-studies.html (Accessed 28 May 2013).
51. Yang Z, Slavin MJ, Sachdev PS. Dementia in the oldest old. Nat Rev Neurol 2013; 9: 382-93.
52. Fratiglioni L, Qiu C. Epidemiology of dementia. In: Dening T, Thomas A, eds. Oxford Textbook of Old Age Psychiatry, 5th ed. New York: Oxford University Press Inc., 2013.
53. Zahs KR, Ashe KH. 'Too much good news' - are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? Trends Neurosci 2010; 33: 381-9.
54. Mudher A, Lovestone S. Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci 2002; 25: 22-6.
55. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vas Health Risk Manag 2010; 6: 775-85.
56. Breitner JC, Baker LD, Montine TJ et al. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement 2011; 7: 402-11.
57. Vellas B, Coley N, Ousset PJ et al. Long-term use of standardised Ginkgo biloba extract for the prevention of Alzheimer's disease (GuidAge): a randomised placebo-controlled trial. Lancet Neurol 2012; 11: 851-9.
58. Peters R, Beckett N, Forette F et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-9.
59. Daviglus ML, Bell CC, Berrettini W et al. National Institutes of Health State-of-the-Science Conference statement: preventing alzheimer disease and cognitive decline. Ann Intern Med 2011; 153: 176-81.
60. Shumaker SA, Legault C, Kuller L et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004; 291: 2947-58.
61. Shumaker SA, Legault C, Rapp SR et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003; 289: 2651-62.
62. Kronos_Longevity_Research_Institute. Hormone Therapy Has Many Favorable Effects in Newly Menopausal Women: Initial Findings of the Kronos Early Estrogen Prevention Study (KEEPS). 2012. http://www.menopause.org/docs/agm/general-release.pdf?sfvrsn=0 (Accessed 3 October 2012).
63. Joas E, Backman K, Gustafson D et al. Blood pressure trajectories from midlife to late life in relation to dementia in women followed for 37 years. Hypertension 2012; 59: 796-801.
64. Qiu C, Winblad B, Fratiglioni L. The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005; 4: 487-99.
65. Richard E, Andrieu S, Solomon A et al. Methodological challenges in designing dementia prevention trials - the European Dementia Prevention Initiative (EDPI). J Neurol Sci 2012; 322: 64-70.
66. Dehnel T. The European Dementia Prevention Initiative. Lancet Neurol 2013; 12: 227-8.
67. McGill University and the Douglas Institute. The PREVENT-Alzheimer program. http://www.douglas.qc.ca/page/prevent-alzheimer. (Last accessed 03.01.2014).
68. Carrillo MC, Brashear HR, Logovinsky V et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement 2013; 9: 123-31.e1.
69. Liu-Ambrose T, Eng JJ, Boyd LA et al. Promotion of the mind through exercise (PROMoTE): a proof-of-concept randomized controlled trial of aerobic exercise training in older adults with vascular cognitive impairment. BMC Neurol 2010; 10: 14.
70. Alzforum. NIH Funds Four Clinical Trials in ADCS Renewal, 2013. http://www.alzforum.org/new/detail.asp?id=3380 (Accessed 8 April 2013).
71. Schmand B, Eikelenboom P, van Gool WA. Value of diagnostic tests to predict conversion to Alzheimer's disease in young and old patients with amnestic mild cognitive impairment. J Alzheimers Dis 2012; 29: 641-8.
72. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007; 69: 2197-204.
73. Green RC, Cupples LA, Go R et al. Risk of dementia among white and African American relatives of patients with Alzheimer disease. JAMA 2002; 287: 329-36.
74. FDA. Alzheimer's disease: developing drugs for the treatment of early stage disease. Draft guidance. In: U.S. Department of Health and Human Services FDA, Center for Drug Evaluation and Research, ed. 2013; 1-7.
75. EMA. Qualification opinion of Alzheimer's disease novel methodologies/biomarkers for PET amyloid imaging (positive/negative) as a biomarker for enrichment for use in predementia AD clinical trials. European Medicines Agency, 2011.
76. Aisen PS, Andrieu S, Sampaio C et al. Report of the task force on designing clinical trials in early (predementia) AD. Neurology 2011; 76: 280-6.
77. Khachaturian ZS, Cami J, Andrieu S et al. Creating a transatlantic research enterprise for preventing Alzheimer's disease. Alzheimers Dement 2009; 5: 361-6.
78. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol 2011; 10: 819-28.
79. Ritchie K, Carriere I, Ritchie CW, Berr C, Artero S, Ancelin ML. Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ (Clinical Research ed) 2010; 341: c3885.
80. Commenges D, Letenneur L, Joly P, Alioum A, Dartigues JF. Modelling age-specific risk: application to dementia. Stat Med 1998; 17: 1973-88.
81. Khachaturian ZS, Petersen RC, Snyder PJ et al. Developing a global strategy to prevent Alzheimer's disease: Leon Thal Symposium 2010. Alzheimers Dement 2011; 7: 127-32.
82. Miller G. Alzheimer's research. Stopping Alzheimer's before it starts. Science (New York, NY) 2012; 337: 790-2.
83. Roses AD, Welsh-Bohmer KA, Burns DK et al. A Pharmacogenetics-Supported Clinical Trial to Delay Onset of Mild Cognitive Impairment due to Alzheimer's Disease 5th Conference Clinical Trials on Alzheimer's Disease. Monte Carlo: The Journal of Nutrition, Health & Aging, 2012; 841.
84. Kivipelto M, Solomon A, Ahtiluoto S et al. The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): study design and progress. Alzheimer's & Dementia 2013; 9: 657-65.
85. Carrie I, Van Kan GA, Gillette-Guyonnet S et al. Recruitment strategies for preventive trials. The MAPT study (MultiDomain Alzheimer Preventive Trial). J Nut Health Aging 2012; 16: 355-9.
86. Richard E, Van den Heuvel E, Moll van Charante EP, Achthoven L, Vermeulen M, Bindels PJ, Van Gool WA. Prevention of dementia by intensive vascular care (PreDIVA): a cluster-randomized trial in progress. Alzheimer Dis Assoc Disord 2009; 23: 198-204.
87. McGuinness B, Todd S, Passmore P, Bullock R. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochr Data Syst Rev (Online) 2009; CD004034.
88. Levi Marpillat N, Macquin-Mavier I, Tropeano AI, Bachoud-Levi AC, Maison P. Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis. J Hypertens 2013; 31: 1073-82.
89. Lyketsos CG, Breitner JC, Green RC et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007; 68: 1800-8.
90. ADAPT. The Alzheimer's Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2013; 9: 714-23.
91. Heart H. Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
92. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochr Data Syst Rev (Online) 2009; CD003160.
93. DeKosky ST, Williamson JD, Fitzpatrick AL et al. Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 2008; 300: 2253-62.
94. Kryscio RJ, Abner EL, Schmitt FA et al. A randomized controlled Alzheimer's disease prevention trial's evolution into an exposure trial: the PREADViSE Trial. J Nut Health Aging 2013; 17: 72-5.
95. Pignone M, Phillips C, Mulrow C. Use of lipid lowering drugs for primary prevention of coronary heart disease: meta-analysis of randomised trials. BMJ (Clinical Research ed) 2000; 321: 1-5.
96. de Vries FM, Denig P, Pouwels KB, Postma MJ, Hak E. Primary prevention of major cardiovascular and cerebrovascular events with statins in diabetic patients: a meta-analysis. Drugs 2012; 18: 2365-73.
97. Seshasai SR, Wijesuriya S, Sivakumaran R et al. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 2012; 172: 209-16.
98. Myung SK, Ju W, Cho B et al. Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ (Clinical Research ed) 2013; Jan 18;346:f10.
99. Cuzick J, Sestak I, Bonanni B et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013; 381: 1827-34.
100. Druesne-Pecollo N, Latino-Martel P, Norat T et al. Beta-carotene supplementation and cancer risk: a systematic review and metaanalysis of randomized controlled trials. Int J Cancer 2010; 127: 172-84.
101. Lee EH, Myung SK, Jeon YJ et al. Effects of selenium supplements on cancer prevention: meta-analysis of randomized controlled trials. Nutr Cancer 2011; 63: 1185-95.
102. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257-64.